Literature DB >> 18054863

Noradrenaline modulates transmission at a central synapse by a presynaptic mechanism.

Andrew J Delaney1, James W Crane, Pankaj Sah.   

Abstract

The lateral division of the central amygdala (CeAL) is the target of ascending fibers from the pain-responsive and stress-responsive nuclei in the brainstem. We show that single fiber inputs from the nociceptive pontine parabrachial nucleus onto CeAL neurons form suprathreshold glutamatergic synapses with multiple release sites. Noradrenaline, acting at presynaptic alpha2 receptors, potently inhibits this synapse. This inhibition results from a decrease in the number of active release sites with no change in release probability. Introduction of a presynaptic scavenger of Gbetagamma subunits blocked the effects of noradrenaline, and botulinum toxin A reduced its effects, showing a direct action of betagamma subunits on the release machinery. These data illustrate a mechanism of presynaptic modulation where the output of a large multiple-release-site synapse is potently regulated by endogenously released noradrenaline and suggests that the CeA may be a target for the central nociceptive actions of noradrenaline.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18054863     DOI: 10.1016/j.neuron.2007.10.022

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  58 in total

Review 1.  Role of presynaptic metabotropic glutamate receptors in the induction of long-term synaptic plasticity of vesicular release.

Authors:  Chirag Upreti; Xiao-Lei Zhang; Simon Alford; Patric K Stanton
Journal:  Neuropharmacology       Date:  2012-05-22       Impact factor: 5.250

2.  Encoding of conditioned fear in central amygdala inhibitory circuits.

Authors:  Stephane Ciocchi; Cyril Herry; François Grenier; Steffen B E Wolff; Johannes J Letzkus; Ioannis Vlachos; Ingrid Ehrlich; Rolf Sprengel; Karl Deisseroth; Michael B Stadler; Christian Müller; Andreas Lüthi
Journal:  Nature       Date:  2010-11-11       Impact factor: 49.962

Review 3.  GPCR mediated regulation of synaptic transmission.

Authors:  Katherine M Betke; Christopher A Wells; Heidi E Hamm
Journal:  Prog Neurobiol       Date:  2012-01-28       Impact factor: 11.685

4.  κ-Opioid Receptor Modulation of GABAergic Inputs onto Ventrolateral Periaqueductal Gray Dopamine Neurons.

Authors:  Chia Li; Thomas L Kash
Journal:  Mol Neuropsychiatry       Date:  2019-05-17

5.  Chronic CRF1 receptor blockade reduces heroin intake escalation and dependence-induced hyperalgesia.

Authors:  Paula E Park; Joel E Schlosburg; Leandro F Vendruscolo; Gery Schulteis; Scott Edwards; George F Koob
Journal:  Addict Biol       Date:  2013-12-13       Impact factor: 4.280

6.  Retrograde opioid signaling regulates glutamatergic transmission in the hypothalamus.

Authors:  Karl J Iremonger; Jaideep S Bains
Journal:  J Neurosci       Date:  2009-06-03       Impact factor: 6.167

7.  Metaplasticity of hypothalamic synapses following in vivo challenge.

Authors:  J Brent Kuzmiski; Quentin J Pittman; Jaideep S Bains
Journal:  Neuron       Date:  2009-06-25       Impact factor: 17.173

8.  Gβγ directly modulates vesicle fusion by competing with synaptotagmin for binding to neuronal SNARE proteins embedded in membranes.

Authors:  Zack Zurawski; Brian Page; Michael C Chicka; Rebecca L Brindley; Christopher A Wells; Anita M Preininger; Karren Hyde; James A Gilbert; Osvaldo Cruz-Rodriguez; Kevin P M Currie; Edwin R Chapman; Simon Alford; Heidi E Hamm
Journal:  J Biol Chem       Date:  2017-05-17       Impact factor: 5.157

Review 9.  Gβγ SNARE Interactions and Their Behavioral Effects.

Authors:  Simon Alford; Heidi Hamm; Shelagh Rodriguez; Zack Zurawski
Journal:  Neurochem Res       Date:  2018-05-11       Impact factor: 3.996

10.  Alpha(2)-noradrenergic antagonist administration into the central nucleus of the amygdala blocks stress-induced hypoalgesia in awake behaving rats.

Authors:  J P Ortiz; L N Close; M M Heinricher; N R Selden
Journal:  Neuroscience       Date:  2008-09-03       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.